Gupta R, Morton D
Int J Oncol. 1995 Oct;7(4):741-7. doi: 10.3892/ijo.7.4.741.
Serum samples selected randomly from 106 patients that had histopathologically proven breast cancer, and from 107 self-proclaimed and apparently healthy females were analyzed for the presence of a 90 kD subunit containing glycoprotein TAA-specific immune complexes (IC) by a murine monoclonal antibody based ELISA. The incidence of the glycoprotein antigen specific IC in breast cancer patients was 63% (67/106), as indicated by the normalized ELISA value above 0.410 OD405nm. On the contrary, only 3 (2.8%) of 107 apparently healthy controls had positive ELISA value (p<0.05). Comparison of the glycoprotein TAA-specific IC results in breast cancer patients with evidence of disease with the results of CEA and CA15-3 revealed that the incidence of abnormal values was increased to 91%. Thus, use of the glycoprotein TAA specific-IC marker in conjunction with CEA and/or CA15-3 may prove to be more sensitive than when used alone for immunodiagnosis and immunoprognosis.
从106例经组织病理学证实患有乳腺癌的患者以及107名自称健康的女性中随机选取血清样本，采用基于鼠单克隆抗体的酶联免疫吸附测定法（ELISA）分析是否存在含90 kD亚基的糖蛋白肿瘤相关抗原（TAA）特异性免疫复合物（IC）。以酶联免疫吸附测定标准化值高于0.410 OD405nm为指标，乳腺癌患者中糖蛋白抗原特异性免疫复合物的发生率为63%（67/106）。相反，107名明显健康的对照者中只有3例（2.8%）酶联免疫吸附测定值为阳性（p<0.05）。对有疾病证据的乳腺癌患者的糖蛋白TAA特异性免疫复合物结果与癌胚抗原（CEA）和糖类抗原15-3（CA15-3）结果进行比较，发现异常值的发生率增至91%。因此，糖蛋白TAA特异性免疫复合物标志物与CEA和/或CA15-3联合使用可能比单独使用对免疫诊断和免疫预后更敏感。
